* Biotricity Inc BTCY.OQ BTCY.O is expected to show a
rise in
quarterly revenue when it reports results on February 13
(estimated).
* The Redwood City California-based company is expected to
report
a 24.3% increase in revenue to $2.4 million from $1.93 million
a year ago, according to the mean estimate from 2 analysts,
based on Refinitiv data.
* Refinitiv's mean analyst estimate for Biotricity Inc is
for a
loss of 9 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Biotricity
Inc is
$2, above its last closing price of $0.78.
This summary was machine generated February 10 at 22:32 GMT.
All figures in US dollars unless otherwise stated